Key result
Bariatric surgery transiently reduces warfarin requirements for ~90 days and increases bleeding risk.
Why the study?
The review aimed to provide dosing recommendations for percentage change in weekly warfarin dose and assess rates of thrombotic and bleeding events in patients requiring long-term warfarin therapy after bariatric surgery.
Does bariatric surgery alter the required weekly dose of warfarin in patients requiring long-term anticoagulation?
Systematic Review (n=160)
Does bariatric surgery alter the required weekly dose of warfarin in patients requiring long-term anticoagulation?
Clinicians should consider lowering the weekly warfarin dose by about 25% immediately post-bariatric surgery, with gradual titration back toward baseline by 90 days.
Answers are grounded in this paper and cite their sources.
Warfarin dose reduction and bleeding monitoring warranted post-bariatric surgery; extends evidence for dynamic anticoagulation management in surgical patients.
OBJECTIVE: The objective of this review was to provide dosing recommendations for percentage change in weekly warfarin dose and rates of thrombotic and bleeding events in patients requiring long-term warfarin therapy after bariatric surgery. DATA SOURCES: A comprehensive literature search of PubMed (through April 5, 2021), Cochrane Library, and Google Scholar (through April 5, 2021) databases was completed using the keywords warfarin OR vitamin k antagonist AND bariatric surgery. STUDY SELECTION AND DATA EXTRACTION: Retrospective studies and matched-cohort studies evaluating preoperative and postoperative use of warfarin after bariatric surgery for obesity were considered. Weekly dose defined as sum of daily doses of warfarin for 7 consecutive days was a required outcome to be considered in this review. Patients were excluded from review if post-operative dosage change was not reported. DATA SYNTHESIS: Six studies were included with a total of 160 patients who met the criteria. A decrease in average warfarin dose was seen in all studies, with the largest decrease occurring at 1 month postsurgery followed by an upward trend toward baseline about 90 days postsurgery. While thrombotic events were observed in none of the patients, there was an increased risk of bleeding in patients, particularly in those who underwent roux-en-y gastric bypass (RYGB) surgery. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: The study provides a specific warfarin dosing titration regimen, as well as embolic and bleed risk in post-bariatric surgery population. CONCLUSIONS: Clinicians may consider lowering warfarin weekly dose by about 25% immediately postsurgery, with doses approaching closer to baseline about 90 days postsurgery.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2022) conducted a systematic review in Obesity requiring bariatric surgery and long-term warfarin therapy (n=160). Bariatric surgery in patients on warfarin vs. Preoperative baseline was evaluated on Percentage change in weekly warfarin dose and rates of thrombotic and bleeding events. Warfarin weekly dose decreased post-bariatric surgery, returning toward baseline around 90 days, with an increased risk of bleeding but no thrombotic events observed.
Synapse has enriched 10 related papers. Consider them for comparative context: